ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements with these filters
Chemiesynth (Vapi) Ltd reported un-audited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved these results alongside the statutory auditor's limited review report.
Chemiesynth's board approved allotment of 1 crore unlisted NCRPS at ₹10 par, raising ₹10 Crore. The 7-year, 5% unsecured shares are issued via private placement.
Chemiesynth (Vapi) Ltd notified a board meeting scheduled for 28 October 2026. The agenda includes approval of unlisted NCRPS allotment on private placement basis.
Chemiesynth (Vapi) Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.
Chemiesynth (Vapi) Ltd held its 40th AGM, approving the adoption of financial statements and the reappointment of Mr. Rushabh Mehta as Director. Shareholders also approved an increase in authorised share capital to ₹18.25 Crore.
Chemiesynth (Vapi) Limited has issued a notice for its 40th Annual General Meeting scheduled for September 30, 2026. The filing includes the Annual Report web-link.
Chemiesynth (Vapi) Ltd has scheduled its 40th Annual General Meeting for September 30, 2026. The company also released its Annual Report for the 2025-26 fiscal year.
Chemiesynth (Vapi) Ltd issued a corrigendum to correct clerical errors in the Share Transfer Book Closure and Benpose dates for its upcoming AGM.
Chemiesynth (Vapi) Ltd reported revenue from operations of ₹4.2 Cr (+5.0% YoY) and a net loss of ₹0.6 Cr for Q1 FY27.
Chemiesynth (Vapi) Limited has scheduled a board meeting for August 12, 2026. The board will consider Q1 FY27 financial results and a preference share issuance.
Chemiesynth (Vapi) Ltd reported revenue from operations of ₹5.5 Cr (-17.9% YoY) and net profit of ₹0.6 Cr (+200.0% YoY) for Q4 FY26.
Chemiesynth (Vapi) Limited approved its audited financial results for the year ended March 31, 2026. The company reported a net loss of ₹0.99 Crore.
Chemiesynth (Vapi) Limited scheduled a board meeting for May 27, 2026. Directors will consider and approve audited financial results for the fiscal year ended March 2026.
Chemiesynth (Vapi) Limited confirmed there was no deviation or variation in the use of proceeds for the quarter and year ended March 31, 2026. The company noted it has not raised funds from the public, making the question of fund utilization inapplicable for this period.
Chemiesynth (Vapi) Limited has declared that SEBI Regulation 24A regarding the Annual Secretarial Compliance Report is not applicable for the period ended March 31, 2026. The company qualifies for this exemption as its paid-up equity capital remains below ₹10 Crore and its net worth is below ₹25 Crore.
Chemiesynth (Vapi) Ltd submitted its initial disclosure under the SEBI Large Corporate framework for FY 2026. The company reported outstanding borrowings of ₹9.07 Crore as of March 31, 2026, and confirmed it does not meet the criteria to be identified as a Large Corporate.
Chemiesynth (Vapi) Limited submitted its compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The report, confirmed by Purva Sharegistry (I) Pvt. Ltd., details the dematerialization of 100 equity shares during the period. This is a routine regulatory disclosure with no material impact on financial performance.